A composite of co-polymer of lactic and glycolic acids (PLGA) loaded with gatifloxacine (GFLX), an antibiotics, and a β-tricalcium phosphate (βTCP) porous ceramic body was prepared by a solvent-free process in which no toxic solvent was used. The GFLX-loaded PLGA released GFLX for 8 weeks in Hanks’ balanced solution. The inhibitory zone diameter (26.25±0.95 mm) for GFLX-containing PLGA disk against S. milleri was significantly larger than 18 mm, and comparable to that (24.88±1.6 mm) for the KB paper disk containing 5 μg of GFLX/disk. This means that the GFLX-containing PLGA has the clinical efficacy. The molten PLGA containing GFLX was successfully loaded in the pores and on the surface of the porous βTCP ceramic at 120 °C at a reduced pressure of 0.02 MPa. The composite of GFLX-loaded porous βTCP ceramic would be promising for treating osteomyelitis.